Another group further demonstrated that monocyte-derived IL-1 and IL-6 were the key factors driving CRS in humanized SGM3 (HuSGM3) mice, and they suggested that tocilizumab did not confer protection against delayed lethal neurotoxicity. The gene discussed is IL1B; the disease is congenital rubella syndrome.